Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Subscribe to Newsletter Newsletter   RSS Feeds RSS Feeds

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Region    |    News By Date    |    Business Directory
All Press Releases for September 04, 2005 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version    Bookmark del.icio.us    Diggs



Physicians warn patients about Protopic and Elidel while waiting for a revised warning label
With unknown long term side effects from these eczema creams, LawyersandSettlements.com offers up-to-date information and promotes free case evaluations. 
x-small text small text medium text large text


    /24-7PressRelease/ - ORLANDO, FL, September 04, 2005 - In March, the US Food and Drug Administration (FDA) asked the makers of Protopic and Elidel to include a black box warning on their labels and marketing materials. To date, Novartis and Astellas Pharma Inc. have yet to fulfill this request. In the meantime, family physicians are warning patients and the parents of children with eczema about the risks of these topical creams.

Protopic (Tacrolimus) and Elidel (Pimecrolimus) are two popular steroid-free creams marketed to adults, teens, and children as young as two years old for the treatment of eczema and Atopic Dermatitis. Eczema and Atopic Dermatitis are both persistent skin conditions recognized as red, scaly, itchy skin.

After research and reports linking the skin absorbent ointments to skin cancer and lymphoma, the FDA issued a Public Health Advisory. In one clinical trial, infants and children younger than 2 years of age treated with Elidel had a higher rate of upper respiratory infections than those treated with a placebo cream.

Since the long term side effects of using Protopic or Elidel have not yet been identified, the FDA recommends only using the prescription creams as a last resort and then only for a limited time. The FDA also warns that patients under two years of age or those with weakened immune systems should not use either product.

Elidel is manufactured and marketed by Novartis; in June, Elidel's mid-year sales were down 14% from 2004, totaling $118 million in the US. Protopic, manufactured and marketed by Astellas Pharma Inc. (formerly Fujisawa Pharmaceutical Co.) ended its Chinese year this month with gross sales of $200 million (USD) worldwide.

To support adults and children affected by the use of Protopic or Elidel, LawyersandSettlements.com provides access to free legal evaluations. For more information about the warnings against Protopic and Elidel, visit: https://www.lawyersandsettlements.com/case/protopic or https://www.lawyersandsettlements.com/case/elidel

About Online Legal Services Ltd (OLS) and http://www.lawyersandsettlements.com
OLS is a privately held Internet marketing company. LawyersandSettlements.com offers up-to-date information on legal news, class action lawsuits, personal injury cases, settlement details, product recalls, and more. Consumers can complete free case evaluations and subscribe to free newsletters. Justice for Everyone

Visit us at:
http://www.lawyersandsettlements.com/

Contact us at:
604-608-3435


---
Press release service and press release distribution provided by http://www.24-7pressrelease.com


# # #


Read more Press Releases from Tracy Laxdal:
Other Press Release Headlines:


Press Release Service & Press Release Distribution News Supplied By 24-7PressRelease.com
Press Release Contact Information:
Tracy Laxdal
www.lawyersandsettlements.com

Marketing Manager
E-Mail: Email us Here
Website: Visit Our Website
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release. We are unable to assist you with any information regarding this release. 24-7 Press Release disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.